Changes in US stocks | Amylyx Pharmaceuticals (AMLX.US) surged nearly 51%, Avexitide Phase III Lucidity trial reached the main end

The Zhitong Finance App learned that Amylyx Pharmaceuticals (AMLX.US) surged nearly 51% to $32.33 on Tuesday. According to the news, on August 18, Amylyx announced that its phase 3 Lucidity trial of the GLP-1 receptor antagonist avexitide to treat hypoglycemia PBH after weight loss surgery reached the main end. Compared with placebo, patients had a 55% reduction in grade 2 and grade 3 hypoglycemia events at week 16.

The trial simultaneously reached all secondary endpoints, showed statistically significant and clinically significant decreases in multiple blood sugar monitoring indicators, and Avexitide was generally well tolerated, and there were no serious treatment-related adverse events or weight changes.

According to reports, Amylyx is a clinical-stage pharmaceutical company dedicated to developing novel treatments for communities with high unmet medical needs, and is currently promoting pre-clinical and clinical development projects for endocrine diseases and neurodegenerative diseases. The company plans to submit Avexitide's new drug application to the US Food and Drug Administration FDA by the end of 2026. If approved, it plans to launch a potential commercial listing in 2027.